MediGuide, a subsidiary of Elbit Systems, has allied with Boston Scientific to develop and commercialize technology platforms in the fields of 3D intravascular imaging and intrabody navigation. The agreement includes an equity investment in MediGuide by
MediGuide, a subsidiary of Elbit Systems, has allied with Boston Scientific to develop and commercialize technology platforms in the fields of 3D intravascular imaging and intrabody navigation. The agreement includes an equity investment in MediGuide by Boston Scientific, codevelopment responsibilities for integrating Boston Scientific's device platforms with MediGuide's proprietary guidance system, exclusive global distribution, and an option for Boston Scientific to acquire MediGuide at a future time.
The cornerstone of the alliance is an advanced navigation system developed by the Arlington, VA, company. The Medical Positioning System (MPS) enables real-time tracking of miniature sensors integrated into therapeutic and diagnostic medical devices. These devices register their exact location and orientation utilizing advanced diagnostic systems such as Boston Scientific's intravascular ultrasound system, as well as other diagnostic systems including x-ray angiography, MR, and CT. Boston Scientific and MediGuide plan to integrate the MPS with Boston Scientific's IVUS.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.